In conclusion, since RUNX1 mutations were not linked to worse outcomes in our study, our findings suggest that allo-HSCT, particularly Haplo-HSCT, may improve the prognosis of AML patients with RUNX1 mutations. Here, RUNX1 is linked to acute myeloid leukemia.